Truemeds: The 'Algorithm Pharmacy' Rescuing India’s 95% Out-of-Pocket Medication Households

In 2018, in the film “Dying to Survive,” when the protagonist Cheng Yong risked legal consequences to deliver the Indian generic drug “Glenin” to countless leukemia patients on the brink of desperation, audiences both inside and outside the cinema were struck by a cruel yet real dilemma: How should ordinary people make choices when life confronts exorbitantly priced drugs?

In the film, Cheng Yong’s “smuggling” carries the tragic heroism of a grassroots champion; he used his individual efforts to tear open a gap in drug accessibility, transforming affordable, effective medicines from an unattainable luxury into a lifeline for patients. In real-world India, Truemeds, a telemedicine platform, is continuing the core mission behind the “Drug God” narrative through a more systematic and intelligent AI-plus-healthcare model: ensuring that every patient can afford life-saving medications.

Truemeds, founded in 2019 and headquartered in Mumbai, India, was co-founded by pharmaceutical industry veterans Akshat Nayyar and Kunal Wani. By leveraging technology to help patients switch to more affordable, compliant generic drugs, Truemeds has disrupted India’s decades-old traditional medication-purchasing habits, addressing the pain points of high drug costs and limited choices in the healthcare sector.

Kunal Wani (left) and Akshat Nayyar (right) from: Truemeds official website

Akshat Nayyar and Kunal Wani have many years of in-depth experience in the pharmaceutical industry, having held positions at leading pharmaceutical companies such as Abbott, Boehringer Ingelheim, and Panacea Biotec. They have accumulated extensive expertise in project management, corporate strategy, digital innovation, and brand management, respectively.

In 2019, the two founders keenly identified the core contradiction in India’s healthcare market: while India has over 250 million chronic disease patients with stable monthly medication needs, 95% of pharmaceutical expenditures are paid out-of-pocket by patients, making drug accessibility a significant challenge for the middle class.

At that time, although there were numerous generic drugs on the market whose patent protection had expired—medications that were identical to brand-name drugs in terms of active ingredients and efficacy—they struggled to gain widespread adoption due to limited patient awareness and restricted access channels. To address this issue, the two founders spent nearly nine months conducting in-depth interviews with industry leaders, researching potential customer needs, and iteratively refining their solution. This effort culminated in the establishment of Truemeds, which aims to leverage a combination of technology and services to ensure that affordable, high-quality medications truly reach patients in need.

As an online pharmacy specializing in generic drugs, Truemeds’ core functionality is straightforward: patients submit prescriptions and consult with doctors online through the platform. Leveraging its proprietary self-developed algorithms alongside complimentary telemedicine services, the platform recommends the most cost-effective generic drug alternatives to patients.

Compared with traditional pharmacies, its greatest advantage lies in “affordability.” By directly connecting with top Indian generic drug manufacturers and eliminating intermediaries, users can save 47% to 51% on their average monthly medication costs. This cost-effective and reliable model has gained high recognition from users.

51% Savings on Alternative Medication Costs Source: Truemeds Official Website

Driven by high user stickiness, Truemeds has continued to expand its commercial scale. As of August 2025, the platform’s total user base reached 3 million, with monthly active users stabilizing at 500,000 and cumulative paying customers exceeding 500,000. Revenue performance was equally impressive: total revenue for fiscal year 2024 amounted to INR 5 billion (approximately USD 57 million), representing a year-on-year increase of over 66% and demonstrating strong growth momentum.

Since its inception, Truemeds has enjoyed sustained investor interest. From a $5 million Series A round in its early stages to a $22 million Series B, and culminating in an $85 million Series C co-led by Peak XV Partners and Accel Partners in August 2025, Truemeds has raised a total of $112 million over six years. As these funding rounds progressed, the company’s latest valuation has surged to over $400 million (approximately RMB 2.8 billion).

Truemeds provides patients with cost-effective medication solutions, establishing a comprehensive service system that covers the entire process of “consultation–recommendation–purchase–delivery–management,” achieving efficient coordination and professional support at multiple key stages.

At the core of its business lies the medication recommendation module. Leveraging its proprietary algorithms, Truemeds analyzes drug ingredients, treated conditions, patients’ medical histories, market price fluctuations, and product information from leading Indian generic manufacturers in real time after patients upload their prescriptions. This enables the precise identification of generic alternatives that match the active ingredients and therapeutic efficacy of originator drugs while offering lower prices.

To alleviate patients’ concerns about generic drugs, the platform also employs a team of experienced physicians and pharmacists to provide free online consultation services. Physicians offer personalized medication recommendations based on each patient’s specific condition, while pharmacists address questions regarding the efficacy and quality of generic drugs. Such professional consultations reach millions of instances annually.

In the drug delivery phase, Truemeds has established a distribution network covering over 19,000 postal code areas across India, providing reliable home delivery services whether in bustling cities like Mumbai and Delhi or in remote rural areas. Patients can also track their delivery progress in real time, ensuring both convenience and safety.

Furthermore, the platform provides patients with a one-stop medication management service: intelligent reminders prevent missed doses and delays in prescription renewals; the digital medicine cabinet establishes electronic medication records; and automated prescription refills streamline the long-term medication purchasing process for patients with chronic diseases, comprehensively enhancing the convenience of medication management.

Truemeds’ three core competencies underpin the efficient operation of these businesses and services.

First is technological leadership.Its algorithm integrates big data analytics, AI-driven screening, and medical expertise to not only rapidly generate precise medication recommendations but also continuously track the latest pharmaceutical information and medical research findings, dynamically optimizing recommendation logic. This capability has become a key factor in attracting patients and enhancing user experience.

Next is ultimate affordability.By directly partnering with India’s top generic drug manufacturers and eliminating intermediaries, the platform passes cost savings on to patients, making its generic drugs more price-competitive than those offered by traditional pharmacies and similar platforms. Meanwhile, it rigorously screens partner manufacturers to precisely attract price-sensitive patient populations.

Finally, there is end-to-end service.The platform offers a closed-loop service spanning from consultation to delivery, enabling patients to meet their medication needs without the hassle of navigating multiple channels. This approach saves time and effort compared to traditional models of seeking medical care and purchasing medicines, while also providing more comprehensive and attentive support than single-function platforms. By optimizing service details, the platform enhances patient satisfaction and loyalty, thereby fostering high user stickiness.

From algorithm-driven precision recommendations for generic drugs, to free professional telemedicine consultations, and further to reliable nationwide delivery across India and one-stop medication management, every aspect of Truemeds is designed to create a seamless, reassuring, and cost-effective experience for patients. Its leading algorithms, source-direct supply chain, and human-centric service design have redefined the deeper meaning of “value for money.”

The development of Truemeds reflects the booming growth potential of the telemedicine market.

From a global perspective, the telemedicine market is in a phase of rapid expansion. Driven by continuous innovations in internet and communication technologies, demand for convenient and efficient medical services continues to rise. Telemedicine has effectively broken down geographical barriers, enabling high-quality healthcare resources to reach regions with relatively weak medical infrastructure.

In developed countries such as those in Europe and the United States, telemedicine has been widely applied in areas including chronic disease management, rehabilitative care, and mental health, significantly alleviating systemic pressures caused by the uneven distribution of medical resources.

Focusing on the domestic market, statistical data from the National Health Commission of China in 2024 shows that the scale of China's telemedicine market has exceeded 800 billion yuan, representing a fourfold increase compared to 2019. This rapid development has been driven by multiple factors.

First,Technology for All, with the national 5G base station coverage rate reaching 98% and the network connectivity rate of primary healthcare institutions exceeding 90%, laying a solid foundation for the stable operation of telemedicine systems. Second,Policy Breakthrough, in 2023, the National Healthcare Security Administration included 12 categories of telemedicine services in the reimbursement scope, significantly stimulating service demand. Third,Surge in Demand, the annual average growth rate of online follow-up consultations for chronic diseases reached 67%, with the peak volume of remote consultations during the pandemic exceeding 1.5 billion visits, demonstrating a rapid increase in public acceptance.

The development of telemedicine is reflected not only in the expansion of market size but also in the innovation of service models and the optimization of healthcare resource allocation. By leveraging online platforms to facilitate cross-temporal and cross-spatial connections between doctors and patients, it provides flexible and personalized services, including online consultations, electronic prescriptions, medication delivery, and chronic disease management.

Meanwhile, by strengthening collaboration with primary healthcare institutions and specialized medical teams, telemedicine has facilitated the sharing and downward distribution of high-quality resources, thereby alleviating the imbalance in resource allocation to a certain extent and enhancing overall service efficiency and accessibility.

Despite the many challenges telemedicine still faces—such as data security, cross-regional regulation, and user habits—its core value in improving the accessibility of medical services and optimizing resource allocation can no longer be overlooked. This is precisely the fundamental reason why companies like Truemeds have achieved sustained growth and attracted investor interest.

The telemedicine market presents both opportunities and challenges, as the industry continues to seek balance and breakthroughs among trust, regulation, and efficiency. Pioneers like Truemeds are more than just platforms; they have become key nodes connecting healthcare equity with the universal accessibility of technology. They are reshaping the system—systematically ensuring that lives are not forced into difficult choices due to medication costs.

In the film, Cheng Yong fights against the system as an individual, opening a window for patients; in reality, Truemeds is leveraging algorithms and systemic power to open a door for hundreds of millions of ordinary households in India, allowing the mission of the “Drug God” to take root through a sustainable model.